Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (NCT07059091)
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)
🩺 Plain-English Summary (8th-Grade Level)
This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each participant will be in the study for about 16 months, including 1-3 months of screening, 12 months of receiving the study drug at a clinic, and a follow-up call one month after your final clinic visit.
Who can join: Review the eligibility criteria below.
Location: University of Alabama — Birmingham, Alabama
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- University of Alabama — Birmingham, Alabama
- University of Arizona- Tuscon — Tucson, Arizona
- University of San Francisco — San Francisco, California
- National Jewish Health — Denver, Colorado
- University of Florida — Jacksonville, Florida
- University of Illinois at Chicago — Chicago, Illinois
- Northwestern University — Chicago, Illinois
- Rush University Medical Center — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- University of Kansas Medical Center — Kansas City, Kansas
- Johns Hopkins University — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Health — Detroit, Michigan
- Mount Sinai, Icahn School of Medicine — New York, New York
- Columbia University — New York, New York
- Cornell University — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Temple University — Philadelphia, Pennsylvania
- University of Pittsburgh — Pittsburgh, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- Baylor College of Medicine — Houston, Texas
- University of Vermont — Colchester, Vermont
- Pacific Northwest Airways - VA Puget Sound Healthcare System, Seattle — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (410) 502-9048
Email: klong33@jhu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Obstructive Pulmonary Disease (COPD)
- Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke — Pleasanton, California
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Birmingham, Alabama
- WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor). — Baltimore, Maryland
- Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations — Durham, North Carolina
- Multi-Center Clean Air Randomized Controlled Trial in COPD — Birmingham, Alabama
- To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — Phoenix, Arizona
Explore by condition: All Chronic Obstructive Pulmonary Disease (COPD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.